A biopharmaceutical company that discovers, develops and commercializes therapies in oncology and dermatology, with lead products including the JAK inhibitor Jakafi.
| Filer | 13FScore | This quarter | Shares | Value | % of their book |
|---|---|---|---|---|---|
| Larry Robbins / Glenview | 61 | New buy | 5,000 | $606,750 | 0.0% |
| Bridgewater | 55 | Added +21% | 203,799 | $24,731,009 | 0.1% |
| Ancora | 42 | Added +18% | 296 | $35,920 | 0.0% |
| Filed | Form | Activist | % of class | Conviction | |
|---|---|---|---|---|---|
| 2026-05-11 | SCHEDULE 13D/A | BAKER BROS. ADVISORS LP | 15.6% | High | filing |
| 2026-02-10 | SCHEDULE 13D/A | BAKER BROS. ADVISORS LP | 15.7% | High | filing |
Every tracked holder of this name, sorted new → added → flat → trimmed. Shares = reported 13F share count; Value as reported (a few managers file values in $thousands). Generated 2026-11-17.